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                                  INTRODUCTION
1. 1NTRODUCTION
         Analytical chemistry plays an increasingly important role in the pharmaceutical industry
where, aside from QA, it is used in discovery of new drug candidates and in clinical applications
where understanding the interactions between the drug and the patient are critical.  Analytical
chemistry is defined as the science and art of determining the composition of material in terms of
elements  or  compounds  contained  in  it1 .  Analytical  chemistry is  divided  into  two branches
quantitative and qualitative.. A qualitative method is the information about the identity of atomic
or  molecular  species  or  functional  groups  in  the  sample.  A quantitative  method  provides
numerical information as to the relative amount of one or more of these components.
For analysis of these drugs different analytical methods are routinely being used. These
analytical methods are classified as chemical and instrumental.  The chemical methods include
Gravimetric and Titrimetric. These methods are simple but less precise and more time consuming
so now days these methods are not suggested for the routine analysis. The instrumental methods
include  electrochemical  methods  -  Electro  gravimetric  method,  Potentiometry,  Colorimetry,
Conductometry,  Polarography and Optical  methods - Absorption and Emission methods.  The
Absorption methods include Visible Spectrophotometry, Ultraviolet Spectrophotometry, Atomic
Absorption  Spectrophotometry,  Infrared  Spectrophotometry,  and  Emission  methods  include
Emission  Spectroscopy,  Flame  Photometry,  Fluorimetry,  etc.  The  other  outstanding  methods
include  isotopes,  radioactivity,  X-ray  fluorescence  and  separation  methods  as  various
chromatographic principles viz. HPLC, GC, HPTLC, LC-MS2 .
Pharmaceutical  analysis  plays  a  major  role  today,  and  it  can  be  considered  as  an
interdisciplinary subject. Pharmaceutical analysis derives its principles from various branches of
science  like  Chemistry,  Physics,  Microbiology,  Nuclear  Science,  Electronics,  etc.  Analytical
method  is  a  specific  application  of  a  technique  to  solve  an  analytical  problem.  Analytical
instrumentation plays an important role in the production and evaluation of new products and in
the  protection  of  consumers  and  the  environment.  This  instrumentation  provides  the  lower
detection limits required to assure safe foods, drugs, water and air3.
HPLC (High performance liquid chromatography)
HPLC is a form of liquid chromatography used to separate compounds that are dissolved
in solution. HPLC instruments consist of a reservoir of mobile phase, a pump, an injector, a
separation column, and a detector. Compounds are separated by injecting a sample mixture onto
the column. The different component in the mixture pass through the column at differentiates due
to differences in their partition behavior between the mobile phase and the stationary phase.
Method development is the process of proving that an analytical method is acceptable for
use in our laboratory to measure the concentration of an API (Active pharmaceutical ingredient)
in  a  specific  compounded  dosage  form.  The development of a method of analysis of any
compound is usually based on  existing  literature, using same or quite similar
instrumentation. But now days HPLC based method is not similar as compare to existing
literature based approaches. The development of new or any improved method should be
beneficial in any way than the  existing method.5 Method development usually requires
selecting the method requirement and deciding the instrumentation to utilize for what purpose.
There are different kinds of reasons for developing new methods for analysis: -
I. There is no any suitable method for a particular compound or combination of that
compound.
II. The existing method may be tedious, contamination-prone or may be not well
suitable.
III. The existing method may be too expensive, time consuming or may not be easily
automated.
IV. The existing method may be having less accuracy or precision.
V. The existing method may not provide adequate sensitivity or analyte selectivity in the
sample.
VI. There may be need of alternative method to confirm legal or scientific reasons.
VII. Analytical data originally or turned by existing method.
Then  word  validation  simply  means,  “Assessment  of  validity”  or  action  of  proving
effectiveness. “The objective of validation of an analytical procedure is to demonstrate that it is
suitable for its intended purpose. “According to ICH Guideline Federal Method Validation is an
Error assessment process.
The  quality  of  analytical  data  is  a  key factor  in  the  success  of  a  drug  development
programme.  The process  of  method  development  and  validation  has  a  direct  impact  on  the
quality of these data, to trust the method, Regulatory requirement. Method validation is required
for the reasons like Assuring quality, achieving the acceptance of the product by International
Agencies,  mandatory  requirement  purpose  for  accreditation  as  per  ISO  19025  guidelines,
mandatory requirement for registration of any pharmaceutical product or pesticide formulation,
validated  methods  are  only applicable  for  proficiency  testing,  analytical  methods  should  be
validated  unless  the  method  employed  is  included  in  the  relevant  pharmacopoeia  or  other
recognized standard reference.6
Validation parameters
Validation of analytical methods is an essential but time - consuming activity for most
analytical development laboratories. It is therefore important to understand the requirements of
method  validation  in  more  detail  and  the  options  that  are  available  to  allow  for  optimal
utilization of analytical resources in a development laboratory. 
Accuracy
The  International  Convention  on  Harmonization  (ICH)  defines  accuracy  is  usually
reported as percent recovery by the assay of known added amount of analyte in the sample or as
the  difference  between  the  mean  and  the  accepted  true  value  together  with  the  confidence
intervals. The range for the accuracy limit should be within the linear range.7
Method Precision
The precision of an analytical procedure expresses the closeness of agreement between a
series of measurements obtained from multiple samples of the same homogeneous sample under
prescribed conditions. Precision is usually investigated at three levels: repeatability, intermediate
precision, and reproducibility.
Repeatability
Repeatability is a measure of the precision under the same operating conditions over a
short interval of time, that is, under normal operating conditions of the analytical method with
the same equipment. It is referred to as intra - assay precision.
Intermediate Precision
Intermediate  precision is  defined as  the variation within the same laboratory.  Typical
parameters that are investigated include day-to-day variation, analyst variation, and equipment
variation.
Reproducibility
Reproducibility  measures  the  precision  between  laboratories.  This  parameter  is
considered in the standardization of an analytical procedure
Detection Limit
The detection limit (DL) is the lowest amount of analyte in a sample that can be detected
but not necessarily quantities under the stated experimental conditions. The detection is usually
expressed as the concentration of the analyte in the sample, for example, percentage, parts per
million (ppm), or parts per billion (ppb).
Quantitation Limit
The Quantitation Limit (QL) is a characteristic of quantitative assays for low levels of
compounds in sample matrices,  such as  impurities  in bulk drug substances  and Degradation
products in finished pharmaceuticals. The detection is usually expressed as the concentration of
the analyte in the sample, for example, percentage, parts per million (ppm), or parts per billion
(ppb).
Linearity
ICH defines linearity of an analytical procedure as the ability (within a given range) to
obtain test results of variable data (e.g., absorbance and area under the curve) which are directly
proportional to the concentration (amount of analyte) in the sample. At least five concentration
levels should be used. Under normal circumstances, linearity is acceptable with a coefficient of
determination (r2) of 0.997.
Robustness
Robustness of an analytical procedure is a measure of the analytical method to remain
unaffected by small but deliberate variations in method parameters and provides an indication of
its reliability during normal usage.
The HPLC method was considered the choice of estimation, since this method is the most
powerful of all chromatographic and other separative methods. The HPLC method has enabled
analytical chemist to attain great success in solving his analytical problems.
          In this study we have planned to develop a new simple, accurate, precise, RP-HPLC
method  for  simultaneous  estimation  of  Quinapril  and  Hydrochlorothiazide  from  bulk  and
pharmaceutical dosage form.
CHAPTER  2
2. LITERATURE REVIEW
This  literature  review  explores  different  methods  for  the  analytical  development  of
Quinapril and Hydrochlorothiazide in pure form, drug product, combined dosage form and in
different biological fluids. Analytical methods are required to characterize drug substances and
drug products composition during all phases of pharmaceutical development. Many experiments
have been performed in different countries to determine the Quinapril and Hydrochlorothiazide
by HPLC, UPLC, LC-MS, TLC and HPTLC methods which are summarized below.
UV-Visible spectroscopy has a simple, sensitive, accurate and reproducible method has
been developed for  simultaneous estimation of  both the drugs  by the Simultaneous equation
method,  using  methanol  as  solvent.  The  two  wavelengths  257  nm  λmax  of  Quinapril
Hydrochloride (QNA-H) and 271 nm λmax of Hydrochlorothiazide (HCTZ) were selected for
the formation of Simultaneous equations. The two drugs follow Beer-Lambert’s law over the
concentration range of 5- 30 µg/ ml of QNA-H and 2.5 – 15 µg/ ml of HCTZ. Recovery study
was  performed  to  confirm  the  accuracy  of  the  method.  The  recovery  of  the  Quinapril
Hydrochloride and Hydrochlorothiazide were found near to 100 %. The Results were found to
satisfactory and reproducible. The methods were validated as per ICH guidelines. The proposed
methods  have  been  applied  successfully  to  the  analysis  of  cited  drugs  in  pharmaceutical
formulations9. 
A Reversed-Phase High Performance Liquid Chromatographic (RP-HPLC) method for
the  simultaneous  determination  of  quinapril  (QNP)  and  hydrochlorothiazide  (HCZ)  in
pharmaceutical  dosage  forms.  In  this  method  quinapril,  hydrochlorothiazide  and  perindopril
(internal standard) were separated using a reversed phase column (Hichrom C18; 250 ×4.6 mm
i.d.; 10 µm) with acetonitrile: potassium dihydrogen phosphate (at pH 2.5; 0.067 M) (40:60 v/v)
as a mobile phase.  UV visible detector set  at 211 nm and mobile phase was pumped at  1.0
mL/min flow rate. The chromatographic separation was performed at 25oC. In these conditions
the retention times for quinapril,  hydrochlorothiazide and perindoprile were 4.391, 3.237 and
3.931 min, respectively. Linearity was obtained in the concentration range of 2-30 µg/ mL for
quinapril and 1.25-18.75 µg/ mL for hydrochlorothiazide. The proposed method has been fully
validated and allows a number of cost- and time-saving benefits. It was successfully applied to
the determination of QNP and HCZ in synthetic mixtures and in pharmaceutical dosage forms.
The proposed method is simple, rapid and suitable for quality control (QC) applications10.
A new simple, sensitive, rapid, accurate, precise and economical RPHPLC method for the
simultaneous determination of Quinapril  HCl (QUI) and Hydrochlorthiazide (HCTZ) in their
combined pharmaceutical dosage form was developed. In RP-HPLC analysis was carried out
using potassium Dihydrogen Phosphate buffer (pH 4.0 adjusted with Ortho Phosphoric acid)
:Acetonitrile(70:30 v/v) mobile phase, andC18 column ODS(100 mm x 4.6 mm, 3.0 µ particle
size) as stationary phase with detection wavelength of 215 nm. Linearity was obtained in the
concentration range of 5-25 µg/ ml for both the drugs. The % recoveries of the both the drugs
were found to be 99.50 – 101.50 % and 99.00 –101.06%respectively.The LOD were found to be
0.014 µg/ mL and 0.013 µg/ mL at 215 nm for Quinapril Hydrochloride and Hydrochlorthiazide
respectively. Methods were statistically validated for Accuracy, precision, specificity, LOQ, and
robustness according to ICH guidelines and can be used for analysis of combined dosage form11.
Quinapril  and  quinaprilat  concentrations  were  determined  in  perfusate,  urine,  and
perfusate  ultrafiltrate  using  a  specific  and  sensitive  reversed-phase  high-performance  liquid
chromatographic procedure with radiochemical detection, coupled to liquid scintillation counting
spectrometry. Quinapril and quinaprilat were measured in perfusate and urine after pretreatment
with acetonitrile and subsequent centrifugation. Perfusate ultrafiltrate was used as collected. Two
quinapril  diketopiperazine  metabolites,  PD  109488  and  PD  113413,  were  separated
chromatographically from quinapril,  quinaprilat,  and from each other.  Assay performance for
quinapril and quinaprilat was assessed by examining precision and accuracy of the assay over
four days. Using a 100-µl sample volume, the limit of quantitation for both 3H-quinapril and 3H-
quinaprilat (sp. act. ≈ 2.0 µCi/ µg) was 1 ng/ mL12.
Ion- Pair HPLC was a simple, precise and rapid HPLC method has been developed and
validated for the estimation of quinapril and hydrochlorothiazide simultaneously in combined
dosage  form.  The  mobile  phase  used  was  a  mixture  of  0.1%  v/v  triethylamine  (pH  3.5),
containing 1 mm of hexane sulphonic acid: acetonitrile (30:70% v/v). The detection of quinapril
and hydrochlorothiazide was carried out on photo diode array detector at 220 nm. Results of the
analysis  were  validated  statistically  and  by  recovery  studies.  The  proposed  method  can  be
successfully used to determine the drug contents of marketed formulation13.
A high-performance  liquid  chromatography  (HPLC)  procedure  for  the  simultaneous
determination of  quinapril  and  its  active metabolite  quinaprilat  in  human plasma samples  is
described.  A one-step  solid-phase  extraction  (SPE)  with  C18 cartridges  was  coupled  with  a
reversed-phase HPLC system. The system requires two mobile phases composed of tetra butyl
ammonium hydrogen sulfate (10 mM adjusted to pH 7)-acetonitrile (62:38, v/v) for quinapril,
and  (25:75 v/v)  for  quinaprilat  elution through a  C18 Symmetry column and detection at  a
wavelength of 215 nm. Calibration curves were linear over the ranges 20 to 1,000 ng/ mL for
quinaprilat and 10 to 500 for quinapril. The limits of quantification were 20 and 10 ng/ mL for
quinaprilat and quinapril, respectively. Extraction recoveries were higher than 90% for quinapril
and 80% for quinaprilat. This method has been successfully applied to a bioequivalence study of
quinapril in healthy subjects14.
A novel, specific and sensitive ultra performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS)  method  was  developed  for  the  simultaneous  determination  of
quinapril and its active metabolite quinaprilat in human plasma. The method involves a simple,
one-step extraction procedure coupled with an Acquity UPLC BEH C18 column (100 x 2.1 mm,
i.d., 1.7 microm) with isocratic elution at a flow-rate of 0.2 mL/ min and lisinopril as the internal
standard. Detection was performed on a triple-quadrupole tandem mass spectrometer in multiple
reactions monitoring mode via electrospray ionization. Using 250 microL plasma, the methods
were validated over the concentration range 5.010-500.374 ng/ mL for quinapril and 10.012-
1000 ng/ mL for quinaprilat, with a lower limit of quantification of 5.010 ng/ mL for quinapril
and 10.012 ng/ mL for quinaprilat. The intra- and inter-day precision and accuracy were within
10.0%.  The  recovery  was  85.8,  62.6  and  61.3%  for  quinapril,  quinaprilat  and  lisinopril,
respectively. Total run time was 3.0 min only15.
A accurate, precise and sensitive UV Spectrophotometric method was developed for the
determination of Nebivolol HCl (NEB-H) and Hydrochlorothiazide (HCTZ) in bulk as well as in
the  pharmaceutical  formulation.  Calibration  curves  were  linear  in  range  of  10-80  µg/  mL
(r2=0.999)  and  2-16 µg/  mL (r2=0.998)  at  λmax  of  281  and  271nm for  Nebivolol  HCl  and
Hydrochlorothiazide respectively. The method was validated statistically16.
Quinapril  hydrochloride  and  hydrochlorothiazide  were  simultaneously  determined  by
HPTLC in pharmaceutical formulations. The drugs were separated on silica gel 60 F plates using
suitable  combination  of  solvents  as  mobile  phase.  The  validation  parameters,  tested  in
accordance with the requirements of ICH guidelines, prove the suitability of methods17.
This  work  deals  with  the  simultaneous  determination  of  Captopril  (CAP)  and
Hydrochlorothiazide (HZ) in two-component solid dosage form, without  prior  separation,  by
three  different  techniques  (simultaneous  equation,  absorbance  ratio  method,  and  first-order
derivative  method). Materials  and  Methods  used  in  this  work  was  carried  out  on  Shimadzu
electron  UV1800  double-beam  UV-Visible  spectrophotometer.  The  absorption  spectra  of
reference and test solutions were carried out in 1 cm matched quartz cell over the range of 200-
400 nm. Methanol and distilled water  are used as  solvent. Results  were shown that  the first
method is the application of simultaneous equation. Where the linearity ranges for both the drugs
were 5-35 µg/ mL. The second method is the determination of ratio of absorbance at 271 nm, the
maximum absorption of HZ and isobestic wavelength 209 nm, the linearity ranges for both the
drugs were 10-120 µg/ mL The third method is the first-order derivative method, where the CAP
shows wavelength at 222 nm and HZ shows at 340 nm, and the linearity ranges for CAP and HZ
were 1-30 µg/ mL and 1-40 µg/ mL, respectively. The proposed procedures were successfully
applied for the simultaneous determination of both the drugs in commercial tablet preparation.
The validity of the proposed methods was assessed by applying the standard addition technique
where  the  percentage  recovery  of  the  added  standard  was  found  to  be  99.52±0.214  and
99.00±0.165 using the simultaneous equation method, 99.76±0.684 and 99.58±0.279 using the
graphical  absorbance  ratio  method,  and  99.45±0295  and  99.21±0.678  using  first  derivative
method, for CAP and HZ, respectively. The proposed procedures are rapid, simple, require no
preliminary separation steps, and can be used for routine analysis of both drugs in quality control
laboratories18.
CHAPTER  3
3. AIM AND OBJECTIVE 
The Pharmaceutical industries rely upon quantitative chemical analysis to ensure that the
raw materials used and the final product obtained meets the required specification. The drug and
drug formulations introduced into the market  increasing at an enormous rate.  These drugs or
formulation may be either in the new entities in the market or partial structural modification of
the  existing  drugs  or  novel  dosage  forms  or  multi  component  dosage  forms.  The  multi
component dosage form proves to be effective due to the combined mode of action on the body.
The  complexity  of  dosage  forms  including  the  presence  of  multiple  drug  entities  creates
considerable challenge to the analytical chemist during the development of assay procedure. The
estimation of individual drugs in these multi component dosage forms becomes difficult due to
difficult extraction or isolation procedures.
The literature survey was carried out and revealed that very few methods are reported for
the simultaneous estimation of these drugs in other combinations. Hence an attempt was made to
develop a simple, specific,  rapid,  precise,  accurate,  linear,  validated and cost  efficient  HPLC
method  for  the  simultaneous  estimation  of  Quinapril  and  Hydrochlorothiazide  in  combined
dosage forms was developed.
The main aim of the research was
 To  develop  a  method  for  the  simultaneous  estimation  of  Quinapril  and
Hydrochlorothiazide in bulk and pharmaceutical dosage form and Validate the method
proposed in accordance with ICH guidelines for the intended analytical application.
 To validate the developed RP-HPLC method by using various validation parameters such
as  accuracy,  precision,  linearity,  system  suitability,  robustness,  ruggedness,  limit  of
detection and limit of quantitation.
CHAPTER  4
4. DRUG PROFILE
Hydrochlorothiazide
Structure : 18
IUPAC Name19 :6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfonamide.
Molecular Formula : C7H8ClN3O4S2 
Molecular Weight : 297.74
pKa : 7.9
Description: 
A thiazide diuretic often considered the prototypical member of this class. It reduces the
reabsorption of electrolytes from the renal tubules. This results in increased excretion of water
and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the
treatment  of  several  disorders  including  edema,  hypertension,  diabetes  insipidus,  and
hypoparathyroidism.
Solubility:  
Slightly  or  very  slightly  soluble  in  water;  sparingly  soluble  in  alcohol;  soluble  in
acetone; freely soluble in dimethylformamide; n-butylamine; and solutions of alkali hydroxides;
insoluble in ether, chloroform, and dilute mineral acids.
Melting point : 274C
Category : Anti-hypertensive
  Diuretics
  Sodium chloride symporter inhibitors
Pharmacodynamics : Thiazides such as hydrochlorothiazide promote water loss from the
body (diuretics).  They inhibit  Na+/Cl- reabsorption  from the  distal  convoluted  tubules  in  the
kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are
often used to treat hypertension, but their hypotensive effects are not necessarily due to their
diuretic  activity.  Thiazides  have  been  shown  to  prevent  hypertension-related  morbidity  and
mortality  although  the  mechanism is  not  fully  understood.  Thiazides  cause  vasodilation  by
activating calcium-activated potassium channels (large conductance) in vascular smooth muscles
and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism Of Action     : Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption
in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted
tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride
symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal
convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-
potassium  ATPases  on  the  basolateral  membrane.  Once  sodium  has  entered  the  cell,  it  is
transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an
increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water
reabsorption.  By  blocking  the  sodium-chloride  symporter,  hydrochlorothiazide  effectively
reduces the osmotic gradient and water reabsorption throughout the nephron.
Pharmacokinetics:
Absorption – 50-60%
Protein binding – 67.9%
Metabolism – hydrochlorothiazide is not metabolized
Route of elimination – hydrochlorothiazide is not metabolized but is eliminated rapidly by the
kidney. Hydrochlorothiazide crosses the placental barrier but not the blood barrier and is secreted
in breast milk
Half life – 5.6 – 14.8 hours
Adverse  affects:  The  most  common  signs  and  symptoms  observed  are  those  caused  by
electrolyte  depletion  (hypokalemia,  hypochloremia,  hyponatremia)  and  dehydration  resulting
from excessive diuresis. If  digitalis has also been administered,  hypokalemia may accentuate
cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse
and rat.
Dose : accuretic – 12.5mg tablets
 
Quinapril 
Structure: 20
IUPAC Name21 : (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-
  yl]amino} propanoyl] -1,2,3,4-tetrahydroisoquinoline-
  3-carboxylic acid.
Molecular Formula : C25H30N2O5
Molecular Weight : 438.516 g/mol
Solubility : It is soluble in water, ethanol and methanol.
Melting point : 120 - 130°C
pKa : strongly acidic - 3.6 and basic – 5.7 
Category : Anti-hypertensive
 Angiotensin converting enzyme inhibitors
Description : Quinapril is a prodrug that belongs to the angiotensin-converting
enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid)
following  oral  administration.  Quinaprilat  is  a  competitive  inhibitor  of ACE,  the  enzyme
responsible for the conversion of  angiotensin I  (ATI)  to  angiotensin II  (ATII). ATII regulates
blood pressure and is  a key component of the renin-angiotensin-aldosterone system (RAAS).
Quinapril may be used to treat essential hypertension and congestive heart failure.
Pharmacodynamics22 :  Quinapril  is  a  nonpeptide,  non-sulfhydryl  prodrug  that  is
deesterified to quinaprilat, its major active metabolite following oral administration. Quinaprilat
lowers blood pressure by antagonizing the effect  of the RAAS. The RAAS is a homeostatic
mechanism for regulating hemodynamics, water and electrolyte balance. First, it stimulates the
secretion  of  aldosterone  from  the  adrenal  cortex.  Second,  ATII  stimulates  the  secretion  of
vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland.
Third, ATII increases blood pressure through direct arterial vasoconstriction. In addition to these
major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE
inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in
blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of
bradykinin, a vasodilator. 
Mechanism of Action : Quinaprilat, the principle active metabolite of quinapril competes
with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing
ATII  levels  in  the  body decreases  blood  pressure  by inhibiting  the  pressor  effects  of  ATII.
Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback
inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via
baroreceptors.
Pharmacokinetics : 
Peak plasma concentrations of quinapril occur within one hour following oral administration.
The extent of absorption is at least 60%. 
Protein binding             – 97%.
Metabolism                   – Hepatic
Route of Elimination - Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV
dose
 Half life - Elimination half life is 2 hours with a prolonged terminal phase of 25 hours.
Adverse Reactions / Side Effects: 
Overdose may lead to severe hypotension. LD50=1739mg/kg (orally in mice). The most common
adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea,
fatigue, and nausea/vomiting.
Dose: accupril, quinapril – 20mg tablets.
CHAPTER  5
5. EXPERIMENTAL WORK
5.1. MATERIALS AND METHODS
Experiment’s used
S.NO Name Model Make
1 Analytical balance Denver Secura
2 UV-Visible Spectrophotometer UV-3600 Shimadzu
3 HPLC HP Agilent 1100 Agilent
4 pH meter pH spear Eutech
5 Sonicator Branson 1510
ultrasonic cleaner
Branson
Chemicals used
S.NO Name Specification Grade
1 HPLC water MERCK Milli-Q
2 Acetonitrile MERCK HPLC
3 Potassium dihydrogen
orthophosphate
MERCK HPLC
4 Orthophosphoric acid MERCK HPLC
5 Triethylamine MERCK HPLC
Active pharmaceutical Ingredient (pure drug)
S.NO Name Specification
1 Quinapril and Hydrochlorothiazide Reference standard
 
Marketed Formulation
S.NO Name Manufacturer
1 Accupril H(20+12.5mg) Pfizer limited 
5.2. METHOD DEVELOPMENT
Selection of wavelength:
The known concentration of quinapril and hydrochlorothiazide equivalent to 100 µg mL-1
were weighed separately and dissolved in 100 mL volumetric flasks using mobile phase. The
resulting solutions were scanned in the range of 200-400 nm. 
Determination  of  isobestic  point  of  Hydrochlorothiazide  and  Quinapril  by  UV-Visible
spectrophotometer:
The  scanned  chromatogram  of  Hydrochlorothiazide  and  Quinapril  are  overlaid  and
observed that isobestic point at 210 nm.
HPLC:
Selection of mobile phase:
To progress an accurate and precise RP-HPLC method for simultaneous estimation of
Quinapril and hydrochlorothiazide, their standard solutions were injected into the HPLC system.
Based on literature survey and solubility properties, various composition of mobile phase with
different  flow  rates  were  used  in  order  to  regulate  the  optimized  condition  for  effective
separation of both drugs. A liquid chromatography system consists of HP Agilent 1100 equipped
with isocratic pump and UV detector. The system was controlled by EZ CHROME software. The
flow rate of Quinapril and Hydrochlorothiazide were tried from 0.8 to 1.2 mL. 
Trial-1
Preparation of buffer:
Weigh  accurately  2.72  gm  of  Potassium  dihydrogen  orthophosphate  (KH2PO4)  was
dissolved in 900 mL of milli-Q water into a 1000mL beaker, sonicated and make up to the final
volume  add  0.6  mL  of  Triethylamine  then  adjust  the  solution  to  pH-  4.5  with  dilute
orthophosphoric acid (OPA) solution.
Preparation of mobile phase:
75  mL of  potassium  dihydrogen  orthophosphate  buffer  of  pH  4.5  and  25  mL of
acetonitrile was taken into 100 mL volumetric flask, sonicated for 25 min and filtered.
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving 20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 ml with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette  out  1.0mL  from  stock  solution  A  of  Quinapril  and  stock  solution  B
hydrochlorothiazide  were  mixed  in  a  10 mL volumetric  flask  and  made up  to  volume with
mobile phase to get a mixed standard solution containing 200 µg mL-1  of Quinapril and 125 µg
mL-1 of Hydrochlorothiazide as final concentration.
Chromatographic conditions:
Ten micro liters of sample was injected by using auto injector and chromatogram was
developed using potassium dihydrogen phosphate buffer : acetonitrile (75:25%  v/v) as a mobile
phase. The pH was maintained at 4.5. The flow rate was maintained at        0.8 mL min -1  and
⁰column temperature was maintained at 30 C. Detector wavelength was fixed at 210 nm. Result
obtained was shown in Table 1 and chromatogram was shown in Fig 2.
Trial-2
Preparation of buffer:
Weigh  accurately  2.72  gm  of  Potassium  dihydrogen  orthophosphate  (KH2PO4)  was
dissolved in 900 mL of milli-Q water into a 1000 mL beaker, sonicated and make up to the final
volume  add  0.6  mL  of  Triethylamine  then  adjust  the  solution  to  pH-4.5  with  dilute
orthophosphoric acid (OPA) solution.
Preparation of mobile phase:
70  mL of  potassium  dihydrogen  orthophosphate  buffer  of  pH  4.5  and  30  mL of
acetonitrile was taken into 100 mL volumetric flask, sonicated for 25 min and filtered.
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10ml with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette  out  1.0  mL  from  stock  solution  A  of  Quinapril  and  stock  solution  B
hydrochlorothiazide  were  mixed  in  a  10 mL volumetric  flask  and  made up  to  volume with
mobile phase to get a mixed standard solution containing 200 µg mL-1  of Quinapril and 125 µg
mL-1 of Hydrochlorothiazide as final concentration.
Chromatographic conditions:
Ten micro liters of sample was injected by using auto injector and chromatogram was
developed using potassium dihydrogen phosphate buffer : acetonitrile            (70:30% v/v) as a
mobile phase. The pH was maintained at 4.5. The flow rate was maintained at 0.8 mL min-1 and
⁰column temperature was maintained at 30 C. Detector wavelength was fixed at 210 nm. Result
obtained was shown in Table 2 and chromatogram was shown in Fig 3
Trial-3
Preparation of buffer:
Weigh  accurately  2.72  gm  of  Potassium  dihydrogen  orthophosphate  (KH2PO4)  was
dissolved in 900 mL of milli-Q water into a 1000mL beaker, sonicated and make up to the final
volume  add  0.6  mL  of  Triethylamine  then  adjust  the  solution  to  pH-4.5  with  dilute
orthophosphoric acid (OPA) solution.
Preparation of mobile phase:
75  mL of  potassium  dihydrogen  orthophosphate  buffer  of  pH  4.5  and  35  mL of
acetonitrile was taken into 100 mL volumetric flask, sonicated for 25 min and filtered.
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving 20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 mL with
mobile phase. Pipette out 1mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1 mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette out 1.0 mL from stock solution A of Quinapril and stock solution B hydrochlorothiazide
were mixed in a 10 mL volumetric flask and made up to volume with mobile phase to get a
mixed  standard  solution  containing  200  µg  mL-1  of  Quinapril  and  125  µg  mL-1  of
Hydrochlorothiazide as final concentration.
Chromatographic conditions:
Ten micro liters of sample was injected by using auto injector and chromatogram was
developed using potassium dihydrogen phosphate buffer : acetonitrile (75:35% v/v) as a mobile
phase. The pH was maintained at 4.5. The flow rate was maintained at  0.8 mL min-1 and column
temperature was maintained at 30⁰C. Detector wavelength was fixed at 210 nm. Result obtained
was shown in Table 3 and chromatogram was shown in Fig 4
Trial-4
Preparation of buffer:
Weigh  accurately  2.72  gm  of  Potassium  dihydrogen  orthophosphate  (KH2PO4)  was
dissolved in 900 mL of milli-Q water into a 1000 mL beaker, sonicated and make up to the final
volume  add  0.6  mL  of  Triethylamine  then  adjust  the  solution  to  pH-4.5  with  dilute
orthophosphoric acid (OPA) solution.
Preparation of mobile phase:
60  mL of  potassium  dihydrogen  orthophosphate  buffer  of  pH  4.5  and  40  mL of
acetonitrile was taken into 100 mL volumetric flask, sonicated for 25 min and filtered.
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving 20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 mL with
mobile  phase.  Pipette  out  1  mL and  make  up  to  10  mL to  get  a  final  concentration  of
200 µg mL-1 (stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into
a 10 mL clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase.
Pipette out 1mL (1250 µg mL-1 ) solution and dilute to 10 mL to get a final concentration of 125
µg mL-1 (stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette out 1.0 mL from stock solution A of Quinapril and stock solution B hydrochlorothiazide
were mixed in a 10 mL volumetric flask and made up to volume with mobile phase to get a
mixed  standard  solution  containing  200  µg  mL-1  of  Quinapril  and  125  µg  mL-1  of
Hydrochlorothiazide as final concentration.
Chromatographic conditions:
Ten micro liters of sample was injected by using auto injector and chromatogram was
developed using potassium dihydrogen phosphate buffer : acetonitrile            (60:40% v/v)as a
mobile phase. The pH was maintained at 4.5. The flow rate was maintained at 0.8 mL min-1 and
column temperature was maintained at 30⁰C. Detector wavelength was fixed at 210 nm. Result
obtained was shown in Table 4 and chromatogram was shown in Fig 5.
OPTIMIZED METHOD
Trial-5
Preparation of buffer:
Weigh  accurately  2.72  gm  of  Potassium  dihydrogen  orthophosphate  (KH2PO4)  was
dissolved in 900 mL of milli-Q water into a 1000mL beaker, sonicated and make up to the final
volume  add  0.6  mL  of  Triethylamine  then  adjust  the  solution  to  pH-  4.5  with  dilute
orthophosphoric acid (OPA) solution.
Preparation of mobile phase:
65  mL of  potassium  dihydrogen  orthophosphate  buffer  of  pH  4.5  and  45  mL of
acetonitrile was taken into 100 mL volumetric flask, sonicated for 25 min and filtered.
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 mL with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1 mL (1250 µg mL-1  ) solution and dilute to 10mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette out 1.0 mL from stock solution A of Quinapril and stock solution B hydrochlorothiazide
were mixed in a 10 mL volumetric flask and made up to volume with mobile phase to get a
mixed  standard  solution  containing  200  µg  mL-1  of  Quinapril  and  125  µg  mL-1  of
Hydrochlorothiazide as final concentration.
Chromatographic conditions:
Ten micro liters of sample was injected by using auto injector and chromatogram was
developed using potassium dihydrogen phosphate buffer : acetonitrile (65:35% v/v) as a mobile
phase. The pH was maintained at 4.5. The flow rate was maintained at        0.9 mL min -1  and
column temperature was maintained at 30⁰C. Detector wavelength was fixed at 210 nm. Result
obtained was shown in Table 5 and chromatogram was shown in Fig 6
5.2.1. ASSAY OF QUINAPRIL AND HYDROCHLOROTHIAZIDE
Standard Stock preparation: 
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 ml with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1 mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette out 1.0 mL from stock solution A of Quinapril and stock solution B hydrochlorothiazide
were mixed in a 10 mL volumetric flask and made up to volume with mobile phase to get a
mixed  standard  solution  containing  200  µg  mL-1  of  Quinapril  and  125  µg  mL-1  of
Hydrochlorothiazide as final concentration.
Preparation of test solution:
20 tablets were weighed and crushed into powder equivalent to 250 mg was transferred to
10 mL volumetric flask and dissolve it in 7 mL of diluent and sonicated for 25 min, further the
volume made up with mobile phase and filtered. From the filtered solution 2 mL was pipette out
into a 10 mL volumetric flask and made up to 10 mL with mobile phase.
Procedure:
Inject  10  µl  of  standard  and  sample  solutions  into  the  chromatographic  system and
measure  the  areas  for  the  Quinapril  and  Hydrochlorothiazide  peaks.  Results  obtained  were
shown in Table 6 - 8and Fig 7-8
Amount of drug in tablet was calculated using following formula
                                   Sample area X standard weight 
Amount present =                                                              X Dilution factor
                                    Standard area X sample weight
Percentage purity:
                                    Amount present / label claim X 100
5.3 METHOD VALIDATION
The chromatographic conditions were validated by evaluating linearity, accuracy, method and
system  precision,  limit  of  detection  (LOD),  limit  of  quantitation  (LOQ)  and  robustness  in
accordance with ICH guidelines.
5.3.1 Specificity:
It is evaluated by injecting the blank, placebo and the control sample solution prepared as per the
proposed method to check for the interference if any peak at the retention time of Quinapril and
Hydrochlorothiazide. Results obtained were shown in Fig. 9 – 10.
5.3.2 Linearity and Range: 
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 ml with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1 mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B).  
Preparation of linearity solution (25%):
Pipette out 0.25 ml of solution from stock solution A and B i.e. 50 µg mL-1   of Quinapril
and 31.25 µg mL-1  of Hydrochlorothiazide stock solution respectively was taken in 10 mL of
volumetric flask dilute up to the mark with mobile phase.
Preparation of linearity solution (50%):
Pipette out 0.5 mL of solution from stock solution A and B i.e.100 µg mL-1   of Quinapril
and  62.5  µg  mL-1  of  Hydrochlorothiazide  stock  solution  respectively  was  taken  in  10  mL
volumetric flask dilute up to the mark with mobile phase.
Preparation of linearity solution (75%):
Pipette out 0.75 mL of solution from stock solution A and B i.e.150 µg mL-1   of Quinapril
and  93.75  µg mL-1 of  Hydrochlorothiazide  stock  solution  respectively was  taken  in  10  mL
volumetric flask dilute up to the mark with mobile phase.
Preparation of linearity solution (100%):
Pipette out 1.0 mL of solution from stock solution A and B i.e. 200 µg mL-1 of Quinapril
and  125  µg  mL-1 of  Hydrochlorothiazide  stock  solution  respectively  was  taken  in  10mL
volumetric flask dilute up to the mark with mobile phase.
Preparation of linearity solution (125%):
Pipette out 1.25 mL of solution from stock solution A and B i.e. 250 µg mL-1 of Quinapril and
156.25 µg mL-1 of Hydrochlorothiazide stock solution respectively was taken in      10 mL
volumetric flask dilute up to the mark with mobile phase.
Preparation of linearity solution (150%):
Pipette out 1.5 mL of solution from stock solution A and B i.e. 300 µg mL-1 of Quinapril and
187.5 µg mL-1 of Hydrochlorothiazide stock solution respectively was taken in        10 mL
volumetric flask dilute up to the mark with diluent.
Procedure:
Each level of the above solutions was injected into the chromatographic system and the
peak  area  was  measured.  A  graph  was  plotted  (peak  area  versus  concentration)  and  the
correlation  coefficient  (r2)  was  calculated.  Result  obtained  was  shown  in  Table  9  and
chromatograph was shown in Fig 11 - 18
5.3.3 Method precision:
Standard preparation:
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10ml with
mobile phase. Pipette out 1 mL and make up to 10 mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1 mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette  out  1.0  mL  from  stock  solution  A  of  Quinapril  and  stock  solution  B
Hydrochlorothiazide were mixed in  a  10 mL volumetric flask and made up to volume with
mobile phase to get a mixed standard solution containing 200 µg mL-1  of Quinapril and 125 µg
mL-1  of Hydrochlorothiazide. Pipette out 1 mL from standard 1 into 10 mL volumetric flask and
make  up  the  volume  with  mobile  phase.  Result  obtained  was  shown  in  Table  10  and
chromatogram was shown in Fig 19 – 24.
Procedure: The standard solution was injected for five times and measured the area for
all five injections in HPLC. The %RSD was calculated.
5.3.4 Accuracy:
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10ml with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette  out  1.0  mL  from  stock  solution  A  of  Quinapril  and  stock  solution  B
hydrochlorothiazide  were  mixed  in  a  10 mL volumetric  flask  and  made up  to  volume with
mobile phase to get a mixed standard solution containing 200 µg mL-1  of Quinapril and 125 µg
mL-1 of Hydrochlorothiazide as final concentration.
Preparation of solution (50%): 
Accurately  weighed  and  transferred  0.25  mg  of  quinapril  and  0.25  mg  of
hydrochlorothiazide working standard into a 10 mL clean dry volumetric flask, add       70 mL of
diluent,  sonicated for 25 minutes and make up to the final  volume with diluents  further the
volume made up with diluent and filtered. 
From  the  filtered  solution  about  2  mL of  Quinapril  and  Hydrochlorothiazide  was
pippetted out into a 10 mL volumetric flask and made up to 10 mL with diluent. The solution was
sonicated for 25 min and filtered. Same procedure was repeated for three times. Results observed
were shown in Table 12-13 and chromatogram was shown in Fig 25 – 27.
Preparation of solution (100%):
Accurately  weighed  and  transferred  0.5  mg  of  quinapril  and  0.5  mg  of
hydrochlorothiazide working standard into a 10 mL clean dry volumetric flask, add       70 mL of
diluent,  sonicated for 25 minutes and make up to the final  volume with diluents  further the
volume made up with diluent and filtered.
From the filtered solution about 2 mL of Quinapril and Hydrochlorothiazide was pipette
out  into  a  10  mL volumetric  flask  and  made  up  to  10  mL with  diluent.  The  solution  was
sonicated for 25 min and filtered. Same procedure was repeated for three times. Results observed
were shown in Table 12- 13 and chromatogram was shown in Fig 28 - 30
Preparation of solution (150%):
Accurately  weighed  and  transferred  0.75  mg  of  quinapril  and  0.75  mg  of
hydrochlorothiazide working standard into a 10 mL clean dry volumetric flask, add 7 mL of
diluent ,  sonicated for  5 minutes  and make up to the final  volume with diluents further  the
volume made up with diluent and filtered.
From the filtered solution about 2mL of Quinapril and Hydrochlorothiazide was pipette
out  into  a  10  mL volumetric  flask  and  made  up  to  10  mL with  diluent.  The  solution  was
sonicated for 25 min and filtered. Same procedure was repeated for three times. Result observed
was shown in Table 12-13 and chromatogram was shown in Fig 31 – 33.
Procedure:
The standard solution was injected in triplicate for Accuracy-50%, Accuracy-100% and
Accuracy-150% solutions.
Calculate the amount found and Amount added for Quinapril & Hydrochlorothiazide and
calculate the individual recovery and mean recovery values.
                                       
                                           Sample peak area x weight of standard   
          % Recovery   =                                                                          X 100
        Standard peak area x weight of sample                                                            
5.3.5 Intermediate precision (Ruggedness):
Ruggedness is the degree of reproducibility of results  obtained by the analysis of the
same  sample  under  a  variety  of  normal  test  conditions  i.e,  different  analysts,  laboratories,
instruments, reagents, assay temperatures, small variations in mobile phase, different days etc.
(i.e. from laboratory to laboratory, from analyst to analyst). Acceptance criteria for ruggedness,
the %RSD for the area of five standard injections should not be more than 2%.
Standard preparation:
Preparation of standard stock solution for Quinapril and Hydrochlorothiazide:
Standard stock solution of pure drugs were prepared separately by dissolving     20 mg of
Quinapril with 7 mL diluent into a 10 mL clean dry volumetric flask and make up to 10 ml with
mobile phase. Pipette out 1 mL and make up to 10mL to get a final concentration of 200 µg mL-1
(stock solution A). Dissolve 12.5 mg of Hydrochlorothiazide with 7 mL diluent into a 10 mL
clean dry volumetric flask and made up to 10 mL (1250 µg mL-1) with mobile phase. Pipette out
1 mL (1250 µg mL-1  ) solution and dilute to 10 mL to get a final concentration of 125 µg mL-1
(stock solution B). 
Preparation of standard solution of Quinapril and Hydrochlorothiazide:
Pipette  out  1.0  mL  from  stock  solution  A  of  Quinapril  and  stock  solution  B
hydrochlorothiazide  were  mixed  in  a  10 mL volumetric  flask  and  made up  to  volume with
mobile phase to get a mixed standard solution containing 200 µg mL-1  of Quinapril and 125 µg
mL-1  of Hydrochlorothiazide as final concentration. Result obtained was shown in Table 14 and
chromatogram was shown in Fig 33 – 39.
5.3.6 Robustness:
As part of robustness, deliberate change in the flow rate and mobile phase composition
was made to evaluate the impact on the method. The mixed standard solution is injected in two
replicates  and  %RSD  was  calculated.  Result  obtained  was  shown  in  Table  15  -  18  and
chromatogram was shown in Fig 40 – 47.
5.3.7 LOD and LOQ:
LOD is the smallest concentration of the analyte that gives measurable response (signal to noise
ratio of 3). The LOQ is the smallest concentration of the analyte which gives response that can
be accurately quantified (signal to noise ratio of 10). Results obtained were shown in Table 19
and chromatogram was shown in Fig 48 – 49.
Calculation:
LOD and LOQ of Quinapril and Hydrochlorothiazide were determined by using instrumental
method. LOD and LOQ were calculated by the following formula:
LOD = S/N
LOQ = S/N
CHAPTER  6
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6. RESULTS AND DISCUSSION
6.1 METHOD DEVELOPMENT:
6.1.1 Selection of wavelength:
The isobestic point was found at 210nm with characteristic peak as shown in the Fig. 1
and was selected UV-Visible detector in HPLC analysis of Quinapril and Hydrochlorothiazide.
Isobestic point     : 210nm
    
         Fig. 1: Isobestic point of Quinapril and Hydrochlorothiazide
6.1.2 DEVELOPMENT TRAILS:
Selection of flow rate: 
The flow rate was changed from 0.8-1.2 mL min-1 and the chromatogram was developed.
The drugs eluted with small differences in fronting and tailing except at 1.2 mL min-1 and it was
selected for analysis.
Trial-1
Table No. 1: Chromatographic condition
Parameters                  Description
Column
                 Agilent XDB, C18, 150 x 4.6 mm, 5°.
Mobile Phase                  Phosphate buffer pH 4.5: ACN (75:25)
Diluent                  Mobile phase
Flow rate                  0.8 mL/min
Wavelength                  210nm
Injection mode                  Auto injector (vial)
Injection volume                  10µl
Fig 2: Chromatogram of HCTZ and QUINAPRIL
Observation
            QUINAPRIL was eluted properly but HCTZ was not eluted. So the mobile phase has
been changed for next trial.
Trial-2
Table No. 2: Chromatographic condition
                                    Fig 3: Chromatogram of HCTZ and QUINAPRIL
Observation 
Both HCTZ and QUINAPRIL were eluted properly, but they are not sharp. So the mobile phase
has been changed for next trial.
Parameters  Description
Column Agilent XDB, C18, 150 x 4.6 mm, 5µ.
Mobile Phase Phosphate buffer pH 4.5: ACN(70:30)
Diluent Mobile phase
Flow Rate 0.8mL/min
Wavelength 210nm
Injection mode Auto injector (vial)
Injection volume 10µl
Trial-3
Table No. 3: Chromatographic condition 
Parameters                          Description
Column
                        Agilent XDB, C18, 150 x 4.6 mm, 5µ.
Mobile Phase                         Phosphate buffer pH 4.5: ACN(75:35)
Diluent                         Mobile phase
Flow Rate                         0.8 mL/min
Wavelength                         210nm
Injection mode                         Auto injector (vial)
Injection volume                         10µl
       Fig 4: Chromatogram of HCTZ and QUINAPRIL
Observation 
Irregular peak shape for HCTZ and less response for QUINAPRIL was observed. So the
mobile phase has been changed for next trial.
Trial-4
Table No. 4: Chromatographic condition
Parameters Description
    Column
  Agilent XDB, C18, 150 x 4.6 mm, 5µ.
  Mobile Phase Phosphate buffer pH 4.5:ACN(60:40)
Diluent Mobile phase
Flow Rate 0.8mL/min
Wavelength 210 nm
Injection mode Auto injector (vial)
Injection
volume
10µl
                                        Fig 5: Chromatogram of HCTZ and QUINAPRIL
Observation
         QUINAPRIL run time was found to be more and theoretical plates was not within the limit.
So the flow rate was changed for next trial.
OPTIMISED METHOD
Trial-5
Table No. 5: Chromatographic condition
Parameters Description
Column Agilent XDB, C18, 150 x 4.6 mm, 5µ.
Mobile Phase Phosphate buffer pH 4.5:ACN(65:35)
Diluent Mobile phase
Flow Rate 0.9mL/min
Wavelength 210 nm
Injection mode Auto injector (vial)
Injection
volume
10µl
Fig 6: Chromatogram of HCTZ and QUINAPRIL
Observation
          Resolution, theoretical plates and symmetric factor were found to be within the limit. So
this method was finalized as the optimized method.
ASSAY:
Table 6: Assay data for Quinapril and Hydrochlorothiazide
Assay  determines  the  content  of  specific  components  such  as  Quinapril  and
Hydrochlorothiazide in the given formulation (Accupril) by means of measuring the peak area
values of the standard and sample. The calculation was shown below by substituting the values
in the following formula.
S. No
Standard
Hydrochlorothiazide Quinapril
1 4940155 6445231
2 4937371 6436697
3 4905375 6447105
Avg 4927633 6443011
Table 7: Marketed formulations.
Commercial
formulation
Ingredients Label amount
(mg)
Amount present
(mg)
% purity
Accupril 
Quinapril 20 19.8 98%
Hydrochlorothiazide 12.5 12.25 97%
D 19
Quinapril 20 19.5 97.5%
Hydrochlorothiazide 12.5 12.05 96.4%
Table 8: Assay data for tablets of Quinapril and Hydrochlorothiazide
S.No
Sample 
Hydrochlorothiazide Quinapril
1 4947356 6349954
2 4936963 6364801
3 4942884 6363923
Avg 4942401 6359559
Fig. 7: Standard chromatogram of Quinapril and Hydrochlorothiazide
Fig.8: Chromatogram of marketed formulation of Quinapril and Hydrochlorothiazide
Calculation:
Formula:
       Amount present:
                                   Sample area X standard weight 
                                                                                            X Dilution factor
                                    Standard area X sample weight
      Percentage purity:
                             Amount present/label claim X 100
6.2. METHOD VALIDATION
6.2.1 Specificity:
Specificity  is  the  ability  to  assess  unequivalently  the  analyte  in  the  presence  of
components,  which may be expected to be present.  Typically these might include impurities,
matrix, degradants etc. It  is evaluated by injecting the blank and the control sample solution
prepared as per the proposed method to check for the interference if any peak at the retention
time of Hydrochlorothiazide and Quinapril.
The specificity of the HPLC method was complete separation of Hydrochlorothiazide and
Quinapril was noticed in presence of tablet excipients. In addition there was no interference at
the  retention  time  of  Hydrochlorothiazide  and  Quinapril  in  the  chromatogram  of  placebo
solution.
                                            Fig 9: Chromatogram of blank solution
          Fig 10: Chromatogram of marketed formulation of Hydrochlorothiazide and Quinapril
6.2.2 Linearity:
           Linearity is determined by calculating the regression line using a mathematical treatment
of the results (i.e. least mean squares) vs. analyte concentration. The range of the method is the
interval  between  the  upper  and  lower  levels  of  an  analyte  that  have  been  determined  with
acceptable precision,  accuracy and linearity.  It  is  determined on either a linear or  nonlinear
response curve (i.e. where more than one range is involved) and is normally expressed in the
same units as the test results.
Table 9:
S.No Hydrochlorothiazide Quinapril 
Conc. (µg mL-1) Area Conc. (µg mL-1) Area 
1 31.25 1380726 50 1652079
2 62.5 2644058 100 3328244
3 93.75 4021937 150 5048620
4 125 5258825 200 6637747
5 156.25 6607297 250 8283624
6 187.5 7997686 300 9928603
              
                  Fig. 11: Calibration graph of Hyrochlorothiazide
              
                             Fig. 12: Calibration graph of Quinapril
                   Fig. 13: Chromatogram of Hydrochlorothiazide and Quinapril for Linearity-1
                  Fig. 14: Chromatogram of Hydrochlorothiazide and Quinapril for Linearity-2
                  Fig. 15: Chromatogram of Hydrochlorothiazide and Quinapril for Linearity-3
                 Fig. 16: Chromatogram of Hydrochlorothiazide and Quinapril for Linearity-4
                   Fig. 17: Chromatogram of Hydrochlorothiazide and Quinapril for Linearity-5
                 Fig. 18: Chromatogram of Hydrochlorothiazide and Quinapril for Linearity-6
Acceptance criteria: linear when correlation coefficient is 0.999
Result :
The relationship between the concentration of Hydrochlorothiazide and Quinapril was linear in
the specific range and the correlation coefficient was found to be within the limit. The correlation
coefficient of Hydrochlorothiazide and Quinapril was found to be 0.999 and 0.999.
6.2.3 Precision:
The precision of an analytical method is the degree of agreement among individual test results
obtained when the method is applied to multiple sampling of a homogenous sample. Precision is
a measure of the reproducibility of the whole analytical method (including sampling, sample
preparation and  analysis)  under  normal  circumstances.  Precision  is  determined  by using  the
method to assay a sample for a sufficient number of times to obtain statistically valid results. The
precision is then expressed as the relative standard deviation.
Table 10: Method precision:
Inj Hydrochlorothiazide Quinapril 
Rt AUC Rt AUC
1 2.099 4939962 5.463 6461393
2 2.101 4939495 5.487 6565316
3 2.105 4979099 5.490 6442481
4 2.105 4948693 5.491 6492502
5 2.106 4950701 5.500 6467022
6 2.106 5027492 5.513 6575268
Mean 2.103 4964240 5.491 6500664
SD 0.00294 34200.3 0.01652 56380.9
%RSD 0.13 0.7 0.301 0.9
          Fig. 19: Chromatogram of Hydrochlorothiazide and Quinapril for method precision - 1
         
          Fig. 20: Chromatogram of Hydrochlorothiazide and Quinapril for method precision - 2
        
        Fig. 21: Chromatogram of Hydrochlorothiazide and Quinapril for method precision - 3
        Fig. 22: Chromatogram of Hydrochlorothiazide and Quinapril for method precision - 4
         Fig.  23: Chromatogram of Hydrochlorothiazide and Quinapril for method precision - 5
          Fig. 24: Chromatogram of Hydrochlorothiazide and Quinapril for method precision – 6
Acceptance criteria: % RSD of the sample replicates should not be more than 2.
Result:
In the present study, the % RSD for Hydrochlorothiazide and Quinapril was found to be 0.7 and
0.9 respectively. The % RSD value indicates good degree of precision within the specified range.
6.2.4 System suitability parameters:
The system is suitable for analysis if the relative standard deviation (RSD) of area counts
in the six replicate injections for each peak should not be more than 2.0%. The USP plate count
of peak should not be less than 2000 theoretical plates for HPLC. The tailing factor for each peak
should not be more than 2.0 and the resolution for two peaks should not be less than 2.0. The
results  obtained indicate the good precision of the developed method. The system suitability
parameters were presented in table.
Table 11: System suitability parameters
S. No Parameters Hydrochlorothiazide Quinapril 
1 Theoretical plates 5136 3516
2 Symmetric factor 1.5 1.7
3 Resolution 6.9 6.3
Acceptance criteria: Theoretical plate’s ≥ 2000, symmetric factor ≤ 2.
Result:  From the above table it was concluded that result obtained was within the limit.
6.2.5 Accuracy:
Accuracy is a measure of the closeness of test results obtained by a method to the true value.
Accuracy indicates the deviation between the mean value found and the true value. It was done
by recovery study. The test solutions were prepared by spiking at about 50%, 100%, and 150% of
specification limit to placebo and analyzed by the proposed HPLC method. The percentage and
percentage relative standard deviation of the recovery were calculated and shown in Table 11 -
12 and Fig. 25-33.
Table-12
AMOUNT OF
SPIKED
ACCURACY FOR HYDROCHLOROTHIAZIDE
Peak Area
Amount
of added
(mg)
Amount
recovered
(mg)
%
Recovery
Average
recovery
%
RSD
50%
2440388 6.25 6.18 99.00218
99.72 0.73
2476269 6.25 6.27 100.4578
2457425 6.25 6.23 99.69335
100% 4946928 12.5 12.54 100.344 100.823 0.42
4985881 12.5 12.65 101.1341
4978885 12.5 12.62 100.9922
150%
7463555 18.75 18.92 100.9277
100.814 0.617495944 18.75 19 101.3657
7405940 18.75 18.77 100.1486
Table : 13
AMOUNT OF
SPIKED
ACCURACY FOR QUINAPRIL
Peak Area
Amount
of added
(mg)
Amount
recovered
(mg)
%
Recovery
Average
recovery
%
RSD
50%
3275013 10 10.89 100.8947 100.9286 0.65
3297815 10 10.15 101.5972
3255511 10 10.02 100.2939
100%
6526276 20 20.14 100.5289 100.82 0.47
6580356 20 20.27 101.3619
6528315 20 20.11 100.5603
150%
9859133 30 30.37 101.2448 101.11 0.12
9843137 30 30.32 101.0806
9835361 30 30.3 101.0007
Fig. 25: Chromatogram of Quinapril and Hydrochlorothiazide for 50% spiking -1
Fig. 26: Chromatogram of Quinapril and Hydrochlorothiazide for 50% spiking – 2
                  Fig. 27: Chromatogram of Quinapril and Hydrochlorothiazide for 50% spiking – 3
             Fig. 28: Chromatogram of Quinapril and Hydrochlorothiazide for 100% spiking – 1
             Fig.29: Chromatogram of Quinapril and Hydrochlorothiazide for 100% spiking – 2
               Fig. 30: Chromatogram of Quinapril and Hydrochlorothiazide for 100% spiking – 3
               Fig. 31: Chromatogram of Quinapril and Hydrochlorothiazide for 150% spiking – 1
              Fig. 32: Chromatogram of Quinapril and Hydrochlorothiazide for 150% spiking – 2
                Fig. 33: Chromatogram of Quinapril and Hydrochlorothiazide for 150% spiking – 3
Acceptance criteria: The percentage recovery should be between 98 – 102%
Result:
The obtained percentage recovery of both the drugs was within the limit. 
This indicates that the proposed method was more accurate than the existing method. In our
study the percentage recovery of Hydrochlorothiazide was found to be 99.71, 100.82 and 100.81
from 50%, 100% and 150% sample solutions. For Quinapril it was found to be 100.92, 100.82
and 101.11 from 50%, 100% and 150% sample solutions.
6.2.6 Intermediate precision (Ruggedness):
Ruggedness is the degree of reproducibility of results obtained by the analysis of the sample
under  a  variety  of  normal  test  conditions  i.e.  different  analysts,  laboratories,  instruments,
reagents,  assay temperatures,  small  variations  in  mobile  phase,  different  days  etc.  (i.e.  from
laboratory to laboratory, from analyst to analyst). Acceptance criteria for ruggedness, the % RSD
for the area of five standard injections should not be more than 2%
Table 14: Ruggedness
Analyst 1
Inj 
Hydrochlorothiazide Quinapril
Rt AUC Rt AUC
1 2.079 4947356 5.481 6349954
2 2.083 4936963 5.484 6364801
3 2.084 4962116 5.501 6353063
Analyst 2 4 2.084 4942883 5.504 6363923
5 2.090 4933657 5.521 6344797
6 2.093 4953878 5.577 6356320
Mean 2.085 4946142 5.511 6355476
S.D 0.003574 10650.3 0.03486 7866.0
%RSD 0.17 0.2 0.63 0.1
              Fig. 34: Chromatogram of Hydrochlorothiazide and Quinapril for Ruggedness - 1
             Fig. 35: Chromatogram of Hydrochlorothiazide and Quinapril for Ruggedness - 2
              Fig. 36: Chromatogram of Hydrochlorothiazide and Quinapril for Ruggedness - 3
              Fig. 37: Chromatogram of Hydrochlorothiazide and Quinapril for Ruggedness - 4
              Fig. 38: Chromatogram of Hydrochlorothiazide and Quinapril for Ruggedness - 5
Fig. 39: Chromatogram of Hydrochlorothiazide and Quinapril for Ruggedness - 6
Acceptance criteria: %RSD of the sample replicates should not be more than 2. 
Result:
             The % RSD for Hydrochlorothiazide and Quinapril it was found to be 0.2 and 0.1 in
AUC, respectively. The % RSD value indicates a good degree of precision within the specified
range.
6.2.7 Robustness :
The  robustness  of  an  analytical  procedure  is  a  measure  of  its  capacity  to  remain
unaffected  by  a  small,  but  deliberate  variation  in  the  method  parameters  and  provides  an
indication of  its  reliability during normal usage.  Robustness  of the  method was investigated
under  a  variety of  conditions  including deliberate  changes  in  the temperature,  mobile  phase
composition and change in flow rate. The degree of reproducibility of the results obtained as a
result of small variations in the method parameters has proven that the method is robust.  The
relative standard deviation for the assay value of Hydrochlorothiazide and Quinapril  obtained
under  deliberately modified chromatographic conditions should be less  than 2%. The results
obtained in the present study also indicate the method is robust.
Change in flow rate: ± 0.1
Table 15: Flow rate: 1.1 ml min-1
S.No AUC
Hydrochlorothiazide Quinapril
1 4951359 5681577
2 4985132 5736681
Mean 4968245 5709129
SD 23881.0 1137764
%RSD 0.5 1.8
                                  Fig 40: Effect of change in flow rate: 1.1 ml min-1 (1)
                             Fig 41: Effect of change in flow rate 1.1 ml min-1 (2)
Table 16: Flow rate: 1.3 ml min-1
S. No AUC
Hydrochlorothiazide Quinapril
1 4417838 5681577
2 4419595 5736681
Mean 4418717 5709129
SD 1242.7 38964.1
%RSD 0.1 0.7
                             Fig 42: Effect of change in flow rate 1.3 ml min-1 (1)
                            Fig 43: Effect of change in flow rate 1.3 ml min-1 (2)
Observation:
When  flow rate  was  changed  retention  time  had  changed  significantly,  here  we  can
observe as the flow rate decrease the retention time increases.
Table 17: Change in mobile phase composition: less organic – 10%
S.No AUC
Hydrochlorothiazide Quinapril
1 5004839 6457829
2 4995256 6451940
Mean 5000048 6454885
SD 6775.9 4164.1
%RSD 0.1 0.1
                         Fig 44: Effect of change in organic phase less organic (1)
                        Fig 45: Effect of change in organic phase less organic (2)
Table 18: Change in mobile phase composition: more organic +10%
S. No AUC
Hydrochlorothiazide Quinapril 
1 4997275 6480049
2 4998272 6480896
Mean 4997773 6480472
SD 704.9 598.7
%RSD 0.1 0.1
                             Fig 46: Effect change in organic phase more organic (1)
                          Fig 47: Effect change in organic phase more organic (2)
Observation:
When mobile phase was changed there was change in the Retention time significantly,
here we can observe that as the organic solvent ratio increases the retention time decrease..
6.2.8 Limit of Detection (LOD) and Limit of Quantitation (LOQ):
LOD and LOQ were calculated by using instrumental method
Table 19: Limit of Detection and Quantitation:
Contents Hydrochlorothiazide Quinapril 
LODS/N) 3 3.1
LOQ(S/N) 9.8 9.1
                Fig 48: LOD chromatogram of Hydrochlorothiazide and Quinapril
Fig 49: LOQ chromatogram of Hydrochlorothiazide and Quinapril
Acceptance criteria: LOD should not exceed LOQ
Result: 
LOD and LOQ of Hydrochlorothiazide was found to be 3 and 9.8
LOD and LOQ of Quinapril was found to be 3.3 and 9.1
          SUMMARY AND CONCLUSIONS
7. SUMMARY AND CONCLUSIONS
In the present study, new RP-HPLC method for simultaneous estimation of Hydrochlorothiazide
and Quinapril in bulk and pharmaceutical dosage form was developed. The developed method
was  validation  for  various  parameters  such  as  accuracy,  precision,  ruggedness,  linearity,
robustness, system suitability, specificity, limit of detection and limit of quantitation as per ICH
guidelines.
The results of the studies are summarized as follows
A. Method development:
 Trial 5 was optimized for the method development of deliberately changing the
chromatographic conditions.
 Column  used  was  Agilent  XDB,  C18,  (150  x  4.6  mm,  5µm),  mobile  phase
composition of phosphate buffer (pH 4.5 adjusted with orthophosphoric acid in
the ratio 65:35), Flow rate 0.9 ml min-1. UV detection was carried out at 210nm.
 Assay percentage was found to  be 98% for  Hydrochlorothiazide and 97% for
Quinapril.
B. Validation Parameters:
 The  calibration  was  linear  in  concentration  range  of  50-300  µg  ml-1,  with
correlation  coefficient  0.999  for  Quinapril  and  the  calibration  was  linear  in
concentration range 31.25 – 187.5 µg ml-1  , with correlation coefficient 0.999 for
Hydrochlorothiazide.
 In  precision it  was found that  %RSD is less than 2% which indicates that the
proposed method has good reproducibility.
 The system suitability parameter indicates good resolution of both the peaks > 2.
 In  accuracy the  percentage  recovery of  Hydrochlorothiazide  and  Quinapril,  in
bulk drugs samples was ranged from 99.72% and 100.92% which indicates that
the method was accurate.
 Robustness,  when  flow  rate  was  changed  retention  time  had  changed
significantly; when mobile phase composition was changed there was change in
retention time significantly.
 LOD and LOQ, the limit of detection (LOD) was 3 for hydrochlorothiazide and
9.8  for  Quinapril  and  the  limit  of  quantitation  (LOQ)  was  3.3  for
Hydrochlorothiazide and 9.1 for Quinapril.
Conclusions:
 The  developed  method  was  simple,  precise  and  cost  effective  for  the  simultaneous
estimation of Hydrochlorothiazide and Quinapril  for routine quality control  analysis of these
either  in  bulk  and  pharmaceutical  formulation.  The  developed  method  was  superior  when
compared to the reported method with less retention time and composition of the mobile phase
with good separation.
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9. APPENDIX
% - Percentage.
µg - Microgram
µl  - Microlitre
µm    - Micrometer
ACN   -  Acetonitrile
AUC  - Area under curve
cm  - Centimeter
HPLC                  - High performance liquid 
chromatography
HPTLC                  - High performance thin layer 
chromatography
LOD  - Limit of detection
LOQ - Limit of Quantitation
mg - Milligram
RP-HPLC            - Reverse phase high 
performance liquid 
chromatography
ICH   - International conference of 
harmonisation
min  - Minute
GC -  Gas chromatography
LC-MS                - Liquid chromatography mass 
spectroscopy
FDA - Food and drug administration
WHO - World health organisation
EC - European committee
USP     - United state pharmacopoeia
USFDA    - United state food and drug 
administration
NP-HPLC             - Normal phase high 
performance liquid 
chromatography
mL   - Millilitre
mm    - Millimetre
nm  - Nanometer
avg wt                          - Average weight
RSD - Relative standard deviation
R
2
 
HCTZ 
-
-
Regression coefficient
Hydrochlorothiazide
ZCP  - Zero crossing point
C18  - Carbon 18
v/v                                - Volume by volume
